What is it about?
We use data about the tumor to predict whether a patient will respond to a drug or become resistant to it. The data consists of different combinations of genes which are different for patients where the drugs are effective vs. ineffective.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The method we develop is better at predicting both sensitivity and resistance to a drug, whereas previous approaches (including our own) could predict either sensitivity OR resistance well. This is important because the choice of which drug to use often depends not only on sensitivity or resistance to the drug, but both of these states.
Perspectives
The genes that are found are generally new, they weren't found in previous scientific studies. Nevertheless, they all tend to be implicated in particular types of cancer. Also they seem to be important for controlling the responses of other genes that are known to contribute to the response.
Dr Peter K Rogan
Western University
Read the Original
This page is a summary of: Pathway‐extended gene expression signatures integrate novel biomarkers that improve predictions of patient responses to kinase inhibitors, MedComm, December 2020, Wiley,
DOI: 10.1002/mco2.46.
You can read the full text:
Resources
Contributors
The following have contributed to this page
